Summit Global Investments Has $1.27 Million Stock Holdings in ADMA Biologics, Inc. (NASDAQ:ADMA)

Summit Global Investments grew its stake in ADMA Biologics, Inc. (NASDAQ:ADMA - Free Report) by 40.5% in the first quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 63,814 shares of the biotechnology company's stock after acquiring an additional 18,389 shares during the quarter. Summit Global Investments' holdings in ADMA Biologics were worth $1,266,000 at the end of the most recent quarter.

Other institutional investors and hedge funds also recently modified their holdings of the company. Mark Sheptoff Financial Planning LLC bought a new stake in ADMA Biologics during the 4th quarter worth approximately $35,000. Vision Financial Markets LLC bought a new stake in ADMA Biologics during the 4th quarter worth approximately $51,000. AlphaQuest LLC bought a new stake in ADMA Biologics during the 4th quarter worth approximately $84,000. GF Fund Management CO. LTD. bought a new stake in ADMA Biologics during the 4th quarter worth approximately $85,000. Finally, CIBC Private Wealth Group LLC increased its stake in ADMA Biologics by 137.1% during the 4th quarter. CIBC Private Wealth Group LLC now owns 5,108 shares of the biotechnology company's stock worth $95,000 after purchasing an additional 2,954 shares in the last quarter. 75.68% of the stock is owned by institutional investors.

Insider Activity

In other ADMA Biologics news, Director Lawrence P. Guiheen sold 7,779 shares of the firm's stock in a transaction on Wednesday, May 21st. The stock was sold at an average price of $20.32, for a total transaction of $158,069.28. Following the completion of the sale, the director now owns 114,830 shares of the company's stock, valued at $2,333,345.60. This trade represents a 6.34% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. 3.50% of the stock is currently owned by insiders.

Wall Street Analysts Forecast Growth

A number of analysts recently issued reports on the company. Cantor Fitzgerald reissued an "overweight" rating and set a $25.00 target price on shares of ADMA Biologics in a research note on Tuesday, March 4th. Raymond James raised their price target on shares of ADMA Biologics from $25.00 to $32.00 and gave the stock a "strong-buy" rating in a research note on Thursday, May 8th. Finally, Wall Street Zen cut shares of ADMA Biologics from a "hold" rating to a "sell" rating in a research note on Friday, May 9th. One research analyst has rated the stock with a sell rating, three have given a buy rating and one has given a strong buy rating to the company. Based on data from MarketBeat.com, ADMA Biologics currently has an average rating of "Moderate Buy" and an average target price of $24.25.

ADMA Biologics Stock Up 0.3%

Shares of ADMA traded up $0.07 during mid-day trading on Wednesday, hitting $20.53. 520,742 shares of the company's stock were exchanged, compared to its average volume of 3,673,548. The company has a market cap of $4.90 billion, a PE ratio of 73.32 and a beta of 0.57. The company has a debt-to-equity ratio of 0.48, a current ratio of 7.09 and a quick ratio of 3.26. ADMA Biologics, Inc. has a 52 week low of $9.82 and a 52 week high of $25.67. The company has a 50-day simple moving average of $20.67 and a 200 day simple moving average of $18.87.

ADMA Biologics (NASDAQ:ADMA - Get Free Report) last released its quarterly earnings data on Wednesday, May 7th. The biotechnology company reported $0.14 EPS for the quarter, missing the consensus estimate of $0.16 by ($0.02). The company had revenue of $114.80 million during the quarter, compared to analyst estimates of $116.40 million. ADMA Biologics had a net margin of 17.80% and a return on equity of 53.20%. The company's quarterly revenue was up 40.2% compared to the same quarter last year. During the same period in the previous year, the company posted $0.08 EPS. On average, research analysts forecast that ADMA Biologics, Inc. will post 0.51 earnings per share for the current fiscal year.

About ADMA Biologics

ADMA Biologics, Inc, a biopharmaceutical company, engages in developing, manufacturing, and marketing specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally. The company offers BIVIGAM, an intravenous immune globulin (IVIG) product indicated for the treatment of primary humoral immunodeficiency (PI); ASCENIV, an IVIG product for the treatment of PI; and Nabi-HB for the treatment of acute exposure to blood containing Hepatitis B surface antigen and other listed exposures to Hepatitis B.